Elliott P Vichinsky

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2634316/publications.pdf

Version: 2024-02-01

		9264	7160
416	26,822	74	153
papers	citations	h-index	g-index

432	432	432	12297
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Primary HBB gene mutation severity and longâ€term outcomes in a global cohort of Î²â€thalassaemia. British Journal of Haematology, 2022, 196, 414-423.	2.5	8
2	An update on the US adult thalassaemia population: a report from the CDC thalassaemia treatment centres. British Journal of Haematology, 2022, 196, 380-389.	2.5	4
3	Implications for the metabolic fate of oral glutamine supplementation within plasma and erythrocytes of patients with sickle cell disease: A pharmacokinetics study. Complementary Therapies in Medicine, 2022, 64, 102803.	2.7	5
4	Random Forest Clustering Identifies Three Subgroups of Î²-Thalassemia with Distinct Clinical Severity. Thalassemia Reports, 2022, 12, 14-23.	0.5	3
5	Risk of mortality from anemia and iron overload in nontransfusionâ€dependent Î²â€thalassemia. American Journal of Hematology, 2022, 97, .	4.1	19
6	The effects of glutamine supplementation on markers of apoptosis and autophagy in sickle cell disease peripheral blood mononuclear cells. Complementary Therapies in Medicine, 2022, 70, 102856.	2.7	3
7	A complication risk score to evaluate clinical severity of thalassaemia syndromes. British Journal of Haematology, 2021, 192, 626-633.	2.5	7
8	Iron Deficiency: Implications Before Anemia. Pediatrics in Review, 2021, 42, 11-20.	0.4	8
9	Voxelotor for the treatment of sickle cell disease. Expert Review of Hematology, 2021, 14, 253-262.	2.2	13
10	Survival and causes of death in 2,033 patients with non-transfusion-dependent Î²-thalassemia. Haematologica, 2021, 106, 2489-2492.	3.5	25
11	Voxelotor in adolescents and adults with sickle cell disease (HOPE): long-term follow-up results of an international, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Haematology,the, 2021, 8, e323-e333.	4.6	61
12	Stable to improved cardiac and pulmonary function in children with high-risk sickle cell disease following haploidentical stem cell transplantation. Bone Marrow Transplantation, 2021, 56, 2221-2230.	2.4	10
13	Time to rethink haemoglobin threshold guidelines in sickle cell disease. British Journal of Haematology, 2021, 195, 518-522.	2.5	7
14	The transfusion management of beta thalassemia in the United States. Transfusion, 2021, 61, 3027-3039.	1.6	18
15	Anterior Pituitary Volume in Patients with Transfusion Dependent Anemias: Volumetric Approaches and Relation to Pituitary MRIâ€R2. Clinical Neuroradiology, 2021, , 1.	1.9	1
16	Consensus statement for the perinatal management of patients with Î± thalassemia major. Blood Advances, 2021, 5, 5636-5639.	5.2	6
17	Pituitary iron and factors predictive of fertility status in transfusion dependent thalassemia. Haematologica, 2021, 106, 1740-1744.	3.5	5
18	Long-Term Efficacy and Safety of the Oral Pyruvate Kinase Activator Mitapivat in Adults with Non-Transfusion-Dependent Alpha- or Beta-Thalassemia. Blood, 2021, 138, 576-576.	1.4	5

#	Article	IF	Citations
19	Effect of Inhaled Cannabis for Pain in Adults With Sickle Cell Disease. JAMA Network Open, 2020, 3, e2010874.	5.9	37
20	Influence of sickle cell disease on susceptibility to HIV infection. PLoS ONE, 2020, 15, e0218880.	2.5	10
21	Efficacy and Safety of Voxelotor in Adolescents and Adults with Sickle Cell Disease: HOPE Trial 72-Week Analysis. Blood, 2020, 136, 19-19.	1.4	3
22	Higher Hemoglobin Levels Achieved with Voxelotor Are Associated with Lower Vaso-occlusive Crisis Incidence: 72-Week Analysis from the HOPE Study. Blood, 2020, 136, 31-32.	1.4	11
23	In Utero Stem Cell Transplantation in Patients with Alpha Thalassemia Major: Interim Results of a Phase 1 Clinical Trial. Blood, 2020, 136, 1-1.	1.4	5
24	Three Distinct Groups of Phenotype Severity in Beta-Thalassemia. Blood, 2020, 136, 15-16.	1.4	0
25	Differential Acetone Extraction of Total and Hemoprotein-Unbound Heme to Quantify Heme Binding Capacity of Plasma in Patients with Sickle Cell Disease: The Role of Heme Scavengers. Blood, 2020, 136, 15-15.	1.4	0
26	Identifying Clinical and Research Priorities in Sickle Cell Lung Disease. An Official American Thoracic Society Workshop Report. Annals of the American Thoracic Society, 2019, 16, e17-e32.	3.2	33
27	Evaluation of Mandible Fractures in Patients With Sickle Cell Anemiaâ€"A Nationwide Study. Journal of Oral and Maxillofacial Surgery, 2019, 77, 1418-1422.	1.2	1
28	Vincristine-induced anemia in hereditary spherocytosis. Experimental Biology and Medicine, 2019, 244, 850-854.	2.4	5
29	Safety and efficacy of deferiprone for pantothenate kinase-associated neurodegeneration: a randomised, double-blind, controlled trial and an open-label extension study. Lancet Neurology, The, 2019, 18, 631-642.	10.2	102
30	A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease. New England Journal of Medicine, 2019, 381, 509-519.	27.0	401
31	Mitapivat (AG-348), an Oral PK-R Activator, in Adults with Non-Transfusion Dependent Thalassemia: A Phase 2, Open-Label, Multicenter Study in Progress. Blood, 2019, 134, 2249-2249.	1.4	2
32	Long-Term Clinical Outcomes of Lentiglobin Gene Therapy for Transfusion-Dependent Î²-Thalassemia in the Northstar (HGB-204) Study. Blood, 2019, 134, 4628-4628.	1.4	10
33	Incidence of Vaso-Occlusive Crisis Does Not Increase with Achieving Higher Hemoglobin Levels on Voxelotor Treatment or after Discontinuation: Analyses of the HOPE Study. Blood, 2019, 134, 2313-2313.	1.4	5
34	Correlation of Voxelotor Exposure with Hemoglobin Response and Measures of Hemolysis in Patients from the HOPE Study. Blood, 2019, 134, 1020-1020.	1.4	3
35	Trends in Iron Overload over Past Two Decades: Results from the Natural History of Iron Burden Study with the SQUID Biosusceptometer. Blood, 2019, 134, 961-961.	1.4	0
36	A Pilot Adult Sickle Cell Hematology Clinic in California's Inland Empire Improves Patient Outcome. Blood, 2019, 134, 3470-3470.	1.4	0

#	Article	IF	Citations
37	Development of a Severity Score System for Thalassemia Syndromes. Blood, 2019, 134, 2225-2225.	1.4	1
38	Fertility and Pregnancy in Women with Transfusion-Dependent Thalassemia. Hematology/Oncology Clinics of North America, 2018, 32, 297-315.	2.2	22
39	Epidemiologic and clinical characteristics of nontransfusionâ€dependent thalassemia in the United States. Pediatric Blood and Cancer, 2018, 65, e27067.	1.5	15
40	Gene Therapy in Patients with Transfusion-Dependent Î²-Thalassemia. New England Journal of Medicine, 2018, 378, 1479-1493.	27.0	525
41	Sickle cell disease. Nature Reviews Disease Primers, 2018, 4, 18010.	30.5	764
42	Variability of homozygous sickle cell disease: The role of alpha and beta globin chain variation and other factors. Blood Cells, Molecules, and Diseases, 2018, 70, 66-77.	1.4	28
43	Transfusion practices and complications in thalassemia. Transfusion, 2018, 58, 2826-2835.	1.6	20
44	A Phase 3 Trial of<scp>l</scp>-Glutamine in Sickle Cell Disease. New England Journal of Medicine, 2018, 379, 226-235.	27.0	378
45	Clinical Outcomes of Lentiglobin Gene Therapy for Transfusion-Dependent Î²-Thalassemia Following Completion of the Northstar HGB-204 Study. Blood, 2018, 132, 167-167.	1.4	3
46	Results from Part A of the Hemoglobin Oxygen Affinity Modulation to Inhibit HbS Polymerization (HOPE) Trial (GBT440-031), a Placebo-Controlled Randomized Study Evaluating Voxelotor (GBT440) in Adults and Adolescents with Sickle Cell Disease. Blood, 2018, 132, 505-505.	1.4	3
47	Significantly Improved Long Term Health Related Quality of Life (HRQL) and Neurocognition Following Familial Haploidentical Stem Cell Transplantation (HISCT) Utilizing CD34 Enrichment and Mononuclear (CD3) Addback in High Risk Patients with Sickle Cell Disease (SCD). Blood, 2018, 132, 162-162.	1.4	1
48	Emergency department utilization by Californians with sickle cell disease, 2005â€“2014. Pediatric Blood and Cancer, 2017, 64, e26390.	1.5	40
49	Lifespan care in SCD: Whom to transition, the patients or the health care system?. American Journal of Hematology, 2017, 92, 487-489.	4.1	9
50	Simvastatin reduces vasoâ€occlusive pain in sickle cell anaemia: a pilot efficacy trial. British Journal of Haematology, 2017, 177, 620-629.	2.5	45
51	Longâ€term safety and efficacy of deferasirox in young pediatric patients with transfusional hemosiderosis: Results from a 5Âyear observational study (ENTRUST). Pediatric Blood and Cancer, 2017, 64, e26507.	1.5	16
52	Dietary nonheme iron is equally bioavailable from ferritin or ferrous sulfate in thalassemia intermedia. Pediatric Hematology and Oncology, 2017, 34, 455-467.	0.8	4
53	Encephaloduroarteriosynangiosis (EDAS) in young patients with cerebrovascular complications of sickle cell disease: Single-institution experience. Pediatric Hematology and Oncology, 2017, 34, 100-106.	0.8	8
54	Chronic organ failure in adult sickle cell disease. Hematology American Society of Hematology Education Program, 2017, 2017, 435-439.	2.5	38

#	Article	IF	Citations
55	Systemic Biomarkers Show Elevated Oxidative Stress and Chronic Inflammation in Two Disorders of Neurodegeneration with Brain Iron Accumulation (NBIA). Blood, 2017, 130, 943-943.	1.4	2
56	Sickle cell anemia, thalassemia, and congenital hemolytic anemias. , 2016, , 126-143.		7
57	Favorable outcomes after in utero transfusion in fetuses with alpha thalassemia major: a case series and review of the literature. Prenatal Diagnosis, 2016, 36, 1242-1249.	2.3	39
58	Stroke recurrence in adult sickle cell patients: it is time for action!. Transfusion, 2016, 56, 1001-1004.	1.6	2
59	Non-transfusion-dependent thalassemia and thalassemia intermedia: epidemiology, complications, and management. Current Medical Research and Opinion, 2016, 32, 191-204.	1.9	48
60	Lentiglobin Gene Therapy for Transfusion-Dependent Î²-Thalassemia: Update from the Northstar Hgb-204 Phase 1/2 Clinical Study. Blood, 2016, 128, 1175-1175.	1.4	17
61	Sickle Cell Disease: Management of Complications. , 2016, , 75-87.		0
62	Threshold Ferritin Values to Predict Control of Liver Iron Burden in Thalassemia. Blood, 2016, 128, 4824-4824.	1.4	0
63	Long-Term Therapy with Deferasirox in Young Pediatric Patients with Transfusional Hemosiderosis Completing up to 5 Years of Treatment in the Observational E.N.T.R.U.S.T. Study. Blood, 2016, 128, 2470-2470.	1.4	0
64	Episodic Patterns of High Emergency Department Utilization Among Sickle Cell Disease Patients. Blood, 2016, 128, 316-316.	1.4	0
65	Fertility in transfusionâ€dependent thalassemia men: Effects of iron burden on the reproductive axis. American Journal of Hematology, 2015, 90, E190-2.	4.1	25
66	Is the Medical Home for Adult Patients with Sickle Cell Disease a Reality or an Illusion?. Hemoglobin, 2015, 39, 130-133.	0.8	3
67	Dysregulated arginine metabolism and cardiopulmonary dysfunction in patients with thalassaemia. British Journal of Haematology, 2015, 169, 887-898.	2.5	22
68	Update of Results from the Northstar Study (HGB-204): A Phase 1/2 Study of Gene Therapy for Beta-Thalassemia Major Via Transplantation of Autologous Hematopoietic Stem Cells Transduced Ex-Vivo with a Lentiviral Beta AT87Q-Globin Vector (LentiGlobin BB305 Drug Product). Blood, 2015, 126, 201-201.	1.4	17
69	Epidemiologic and Clinical Characteristics of Thalassemia (Thal) Intermedia (TI) in the United States. Blood, 2015, 126, 3279-3279.	1.4	1
70	The Effects of Glutamine Supplementation on Markers of Autophagy and Apoptosis in Peripheral Blood Mononuclear Cells from Patients with Sickle Cell Disease. Blood, 2015, 126, 3412-3412.	1.4	0
71	NKTT120 Safely Depletes iNKT Cells in Stable Adult Sickle Cell Patients in a Phase 1 Trial. Blood, 2015, 126, 2178-2178.	1.4	0
72	Iron Level and Monocyte Morphology Predict TLR4 Expression and Reactive Oxygen Species Production Which Influences Chronic Inflammation in Î²-Thalassemia. Blood, 2015, 126, 950-950.	1.4	4

#	Article	IF	Citations
73	Mechanisms of plasma nonâ€transferrin bound iron generation: insights from comparing transfused diamond blackfan anaemia with sickle cell and thalassaemia patients. British Journal of Haematology, 2014, 167, 692-696.	2.5	54
74	Transfusion complications in thalassemia patients: a report from the <scp>C</scp>enters for <scp>D</scp>isease <scp>C</scp>ontrol and <scp>P</scp>revention (CME). Transfusion, 2014, 54, 972-981.	1.6	97
75	Validation and reliability of a diseaseâ€specific quality of life measure (the) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 667 Td (<sc>Haematology, 2014, 164, 431-437.	2.5	36
76	Renal medullary carcinoma in an adolescent with sickle cell anemia. Pediatric Blood and Cancer, 2014, 61, 567-567.	1.5	11
77	Population based surveillance in sickle cell disease: Methods, findings and implications from the California registry and surveillance system in hemoglobinopathies project (RuSH). Pediatric Blood and Cancer, 2014, 61, 2271-2276.	1.5	39
78	Emerging Therapy in Hemoglobinopathies: Lessons from the Past and Optimism for the Future. Hematology/Oncology Clinics of North America, 2014, 28, xiii-xviii.	2.2	3
79	Elevated tricuspid regurgitant jet velocity in subgroups of thalassemia patients: insight into pathophysiology and the effect of splenectomy. Annals of Hematology, 2014, 93, 1139-1148.	1.8	14
80	Response to "Efficacy and safety of sildenafil for the treatment of severe pulmonary hypertension in patients with hemoglobinopathies: results from a long-term follow up " Haematologica 2014;99(2):e17-18.. Haematologica, 2014, 99, e19-e19.	3.5	1
81	In utero hematopoietic cell transplantation for hemoglobinopathies. Frontiers in Pharmacology, 2014, 5, 278.	3.5	25
82	NKTT120 Reduces iNKT Cells without Dose Limiting Toxicity in Stable Adult Sickle Cell Patients in a Phase 1 Trial. Blood, 2014, 124, 2718-2718.	1.4	3
83	Comparison of Clinical Outcomes Between Adult and Pediatric Patients (pts) with Sickle Cell Disease (SCD): 3-Year (y) Follow-up in a Prospective, Longitudinal, Noninterventional Registry Trial. Blood, 2014, 124, 4890-4890.	1.4	1
84	Pituitary Iron and Volume Are Affecting Hormones and Reproductive Potential. Blood, 2014, 124, 4048-4048.	1.4	0
85	Impact of Immigration and Migration on Thalassemia Surveillance in California, 2004-2008. Blood, 2014, 124, 4855-4855.	1.4	1
86	Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: Twoâ€year results including pharmacokinetics and concomitant hydroxyurea. American Journal of Hematology, 2013, 88, 1068-1073.	4.1	35
87	Treatment of heart failure in adults with thalassemia major: response in patients randomised to deferoxamine with or without deferiprone. Journal of Cardiovascular Magnetic Resonance, 2013, 15, 38.	3.3	47
88	Pregnancy outcomes in women with thalassemia in North America and the United Kingdom. American Journal of Hematology, 2013, 88, 771-773.	4.1	25
89	Combined chelation therapy with deferasirox and deferoxamine in thalassemia. Blood Cells, Molecules, and Diseases, 2013, 50, 99-104.	1.4	69
90	Non-transfusion-dependent thalassemias. Haematologica, 2013, 98, 833-844.	3.5	231

#	Article	IF	Citations
91	Increased leucocyte apoptosis in transfused Î²â€thalassaemia patients. British Journal of Haematology, 2013, 160, 399-403.	2.5	7
92	Application of Multiplex Ligation-Dependent Probe Amplification to Screen for Î²-Globin Cluster Deletions: Detection of Two Novel Deletions in a Multi Ethnic Population. Hemoglobin, 2013, 37, 241-256.	0.8	10
93	Treatment of Classic Pantothenate Kinaseâ€"Associated Neurodegeneration with Deferiprone and Intrathecal Baclofen. American Journal of Physical Medicine and Rehabilitation, 2013, 92, 728-733.	1.4	27
94	Zinc supplementation improves bone density in patients with thalassemia: a double-blind, randomized, placebo-controlled trial. American Journal of Clinical Nutrition, 2013, 98, 960-971.	4.7	41
95	Clinical Manifestations of Â-Thalassemia. Cold Spring Harbor Perspectives in Medicine, 2013, 3, a011742-a011742.	6.2	82
96	Pain in thalassaemia: the effects of age on pain frequency and severity. British Journal of Haematology, 2013, 160, 680-687.	2.5	29
97	Pain over time and its effects on life in thalassemia. American Journal of Hematology, 2013, 88, 939-943.	4.1	19
98	The palatability and tolerability of deferasirox taken with different beverages or foods. Pediatric Blood and Cancer, 2013, 60, 1507-1512.	1.5	23
99	Human T Cell Lymphotropic Virus Type 1 Infection Among U.S. Thalassemia Patients. AIDS Research and Human Retroviruses, 2013, 29, 1006-1009.	1.1	5
100	A randomized, placebo-controlled trial of arginine therapy for the treatment of children with sickle cell disease hospitalized with vaso-occlusive pain episodes. Haematologica, 2013, 98, 1375-1382.	3.5	130
101	Sildenafil therapy in thalassemia patients with Doppler-defined risk of pulmonary hypertension. Haematologica, 2013, 98, 1359-1367.	3.5	40
102	Inflammatory and Vitamin Bio-Markers Of Iron Trafficking and Distribution In Transfusional Overload: Insights From Comparing Diamond Blackfan Anemia With Sickle Cell Disease and Thalassemia (MCSIO) Tj ETQq0 0 1 0 rgBT /Overlock 10 T	1.4	1
103	Association Of Cardiac Iron By T2* With Innate Immune Markers In Transfusion-Dependent Thalassemia Patients Undergoing Combined Chelation Therapy. Blood, 2013, 122, 3450-3450.	1.4	2
104	Citrate Synthase Activity Is Increased In Children With Sickle Cell Disease (SCD) On Hydroxyurea (HU) Therapy. Blood, 2013, 122, 4690-4690.	1.4	0
105	Abnormal Reproductive Measures and Seminal Plasma Findings in Men With Thalassemia Major (TM) and Iron Overload. Blood, 2013, 122, 4707-4707.	1.4	0
106	Clinical Outcomes For Patients With Sickle Cell Disease: 24-Month Follow-Up In An Ongoing 3-Year, Prospective, Non-Interventional Registry Trial. Blood, 2013, 122, 988-988.	1.4	7
107	Chelation use and iron burden in North American and British thalassemia patients: a report from the Thalassemia Longitudinal Cohort. Blood, 2012, 119, 2746-2753.	1.4	78
108	Advances in the treatment of alpha-thalassemia. Blood Reviews, 2012, 26, S31-S34.	5.7	49

#	Article	IF	Citations
109	Identification of Three Novel Hb F Variants: Hb F-Hayward [^GÎ³1(NA1)Glyâ†'Asp, GGT>GAT], Hb F-Chori-I [^AÎ³^T16(A13)Glyâ†'Asp, GGC>GAC] and Hb F-Chori-II [^AÎ³^I29(B11)Glyâ†'Glu, GGA>GAA]. Hemoglobin, 2012, 36, 305-309.	0.8	3
110	Inadequate Dietary Intake in Patients with Thalassemia. Journal of the Academy of Nutrition and Dietetics, 2012, 112, 980-990.	0.8	39
111	The effect of whole body vibration therapy on bone density in patients with thalassemia: A pilot study. American Journal of Hematology, 2012, 87, E76-9.	4.1	12
112	A phase 1/2 trial of HQKâ€1001, an oral fetal globin inducer, in sickle cell disease. American Journal of Hematology, 2012, 87, 1017-1021.	4.1	30
113	A potent oral Pâ€selectin blocking agent improves microcirculatory blood flow and a marker of endothelial cell injury in patients with sickle cell disease. American Journal of Hematology, 2012, 87, 536-539.	4.1	72
114	Lower alloimmunization rates in pediatric sickle cell patients on chronic erythrocytapheresis compared to chronic simple transfusions. Transfusion, 2012, 52, 2671-2676.	1.6	62
115	Safety of deferasirox in sickle cell disease patients with coâ€existing liver impairment â€“ response to <scp>S</scp>inakos etÂal. British Journal of Haematology, 2012, 157, 506-507.	2.5	0
116	Emerging 'A' therapies in hemoglobinopathies: agonists, antagonists, antioxidants, and arginine. Hematology American Society of Hematology Education Program, 2012, 2012, 271-5.	2.5	14
117	Emerging â€˜Aâ€™ therapies in hemoglobinopathies: agonists, antagonists, antioxidants, and arginine. Hematology American Society of Hematology Education Program, 2012, 2012, 271-275.	2.5	23
118	Sildenafil Therapy in Patients with Thalassemia and an Elevated Tricuspid Regurgitant Jet Velocity (TRV) On Doppler Echocardiography At Risk for Pulmonary Hypertension: Report From the Thalassemia Clinical Research Network. Blood, 2012, 120, 1023-1023.	1.4	2
119	Innate Immune Cell Expression of Pattern Recognition Receptors From Î²-Thalassemia Patients During Intensive Combination Chelation Therapy. Blood, 2012, 120, 1025-1025.	1.4	1
120	Quality Improvement Goals for Sickle Cell Disease Pain Management in an Urban Pediatric Emergency Department: We Can Do Better!.. Blood, 2012, 120, 2101-2101.	1.4	3
121	Interim Safety and Effectiveness Results From a 5-Year Observational Study of Deferasirox in Pediatric Patients Aged 2â€“<6 Years At Enrollment.. Blood, 2012, 120, 2125-2125.	1.4	1
122	The prevention and management of alloimmunization in sickle cell disease: the benefit of extended phenotypic matching of red blood cells. Immunohematology, 2012, 28, 20-23.	0.2	23
123	Renal Medullary Carcinoma in an Adolescent with Homozygous Hemoglobin SS. Blood, 2012, 120, 4774-4774.	1.4	1
124	Cardiopulmonary and Laboratory Profiling of Patients with Thalassemia At Risk for Pulmonary Hypertension: Report From the Thalassemia Clinical Research Network.. Blood, 2012, 120, 2122-2122.	1.4	1
125	Iron Trafficking and Distribution in Transfusional Overload: Insights From Comparing Diamond Blackfan Anemia with Sickle Cell Disease and Thalassemia. Blood, 2012, 120, 995-995.	1.4	2
126	12-Month Follow-up for Patients with Sickle Cell Disease in an Ongoing 3-Year, Prospective, Non-Interventional Registry Trial. Blood, 2012, 120, 1010-1010.	1.4	0

#	Article	IF	Citations
127	Tricuspid Regurgitant Jet Velocity (TRV), Biomarkers of Hemolysis, and Impact of Oxygen Therapy in Children with Sickle Cell Disease (SCD) and Vaso-Occlusive Pain Episodes (VOE). Blood, 2012, 120, 4752-4752.	1.4	0
128	Heterogeneity of Hemoglobin H Disease in Childhood. New England Journal of Medicine, 2011, 364, 710-718.	27.0	136
129	Transfusion and Chelation Practices in Sickle Cell Disease: A Regional Perspective. Pediatric Hematology and Oncology, 2011, 28, 124-133.	0.8	20
130	Characterization of low bone mass in young patients with thalassemia by DXA, pQCT and markers of bone turnover. Bone, 2011, 48, 1305-1312.	2.9	36
131	Risks Factors And Mortality Associated With Doppler-Defined-Pulmonary Hypertension In Thalassemia Major: A Report From The Thalassemia Clinical Research Network Longitudinal Cohort Study. , 2011, , .		1
132	Risk factors and mortality associated with an elevated tricuspid regurgitant jet velocity measured by Doppler-echocardiography in thalassemia: a Thalassemia Clinical Research Network report. Blood, 2011, 118, 3794-3802.	1.4	55
133	A pilot study of subcutaneous decitabine in Î²-thalassemia intermedia. Blood, 2011, 118, 2708-2711.	1.4	73
134	Reproductive capacity in iron overloaded women with thalassemia major. Blood, 2011, 118, 2878-2881.	1.4	57
135	A phase 1 dose-escalation study: safety, tolerability, and pharmacokinetics of FBS0701, a novel oral iron chelator for the treatment of transfusional iron overload. Haematologica, 2011, 96, 521-525.	3.5	37
136	Metabolic Fate Of Oral Glutamine Supplementation Within Plasma And Erythrocytes Of Patients With Sickle Cell Disease And Pulmonary Hypertension: Preliminary Pharmacokinetics Results. , 2011, , .		0
137	A pilot study of the shortâ€term use of simvastatin in sickle cell disease: effects on markers of vascular dysfunction. British Journal of Haematology, 2011, 153, 655-663.	2.5	67
138	Red cell alloimmunization in a diverse population of transfused patients with thalassaemia. British Journal of Haematology, 2011, 153, 121-128.	2.5	108
139	Darbepoetin alfa for the treatment of anaemia in alphaâ€or betaâ€thalassaemia intermedia syndromes. British Journal of Haematology, 2011, 154, 281-284.	2.5	15
140	Longâ€term safety and efficacy of deferasirox (Exjade^{Â®}) for up to 5â€ƒyears in transfusional ironâ€overloaded patients with sickle cell disease. British Journal of Haematology, 2011, 154, 387-397.	2.5	67
141	Novel influenza a (H1N1) viral infection in pediatric patients with sickle-cell disease. Pediatric Blood and Cancer, 2011, 56, 95-98.	1.5	11
142	The mediating effects of family functioning on psychosocial outcomes in healthy siblings of children with sickle cell disease. Pediatric Blood and Cancer, 2011, 57, 1055-1061.	1.5	22
143	Iron chelation adherence to deferoxamine and deferasirox in thalassemia. American Journal of Hematology, 2011, 86, 433-436.	4.1	63
144	Approaches to Transfusion Therapy and Iron Overload in Patients with Sickle Cell Disease: Results of an International Survey. Pediatric Hematology and Oncology, 2011, 28, 37-42.	0.8	16

#	Article	IF	Citations
145	Hemoglobinopathies. , 2011, , 1662-1677.e1.		2
146	Baseline Characteristics of Patients with Sickle Cell Disease in An Ongoing 5-Year, Prospective, Noninterventional Registry Trial. Blood, 2011, 118, 1060-1060.	1.4	4
147	A Randomized Phase II Study Evaluating the Efficacy and Safety of Deferasirox Versus Deferoxamine in Patients with Sickle Cell Disease (SCD): 2-Year Results Including Pharmacokinetics (PK) and Safety of Deferasirox with Concomitant Hydroxyurea Therapy. Blood, 2011, 118, 1082-1082.	1.4	3
148	Transfusion Complications in Thalassemia: A Report From the Centers for Disease Control and Prevention (CDC). Blood, 2011, 118, 340-340.	1.4	1
149	Safety, Tolerability and Dose Response of FBS0701, a Novel Iron Chelator for Treatment of Transfusional Iron Overload: Results of a 24-Week Multicenter, International Phase 2 Study. Blood, 2011, 118, 690-690.	1.4	0
150	Effect of Short-Term Simvastatin Treatment on Endothelial Adhesion Molecules in Sickle Cell Disease: A Pilot Study. Blood, 2011, 118, 1070-1070.	1.4	0
151	Mental Health Symptoms, Quality of Life and Barriers to Accessing Health Care in Sickle Cell Disease. Blood, 2011, 118, 337-337.	1.4	0
152	Oxidative Stress and Reproductive Capacity in Iron Overload Thalassemia Major Women. Blood, 2011, 118, 2155-2155.	1.4	0
153	Evaluation of Moyamoya Disease in Sickle Cell Anemia Patients After Encephaloduroarteriosynangiosis. Blood, 2011, 118, 1059-1059.	1.4	0
154	Hb E/beta-thalassaemia: a common & clinically diverse disorder. Indian Journal of Medical Research, 2011, 134, 522-31.	1.0	37
155	Chart Card: Feasibility of a Tool for Improving Emergency Department Care in Sickle Cell Disease. Journal of the National Medical Association, 2010, 102, 1017-1024.	0.8	7
156	Pulmonary hypertension and NO in sickle cell. Blood, 2010, 116, 852-854.	1.4	59
157	Relationship between Chronic Transfusion Therapy and Body Composition in Subjects with Thalassemia. Journal of Pediatrics, 2010, 157, 641-647.e2.	1.8	28
158	Assessment of cardiac iron by MRI susceptometry and R2* in patients with thalassemia. Magnetic Resonance Imaging, 2010, 28, 363-371.	1.8	17
159	Hemoglobin Hakkari: An autosomal dominant form of beta thalassemia with inclusion bodies arising from de novo mutation in exon 2 of beta globin gene. Pediatric Blood and Cancer, 2010, 54, 332-335.	1.5	8
160	Low dose, oral epsilon aminocaproic acid for renal papillary necrosis and massive hemorrhage in hemoglobin SC disease. Pediatric Blood and Cancer, 2010, 54, 148-150.	1.5	9
161	Education and employment status of children and adults with thalassemia in North America. Pediatric Blood and Cancer, 2010, 55, 678-683.	1.5	10
162	Complexity of alpha thalassemia: growing health problem with new approaches to screening, diagnosis, and therapy. Annals of the New York Academy of Sciences, 2010, 1202, 180-187.	3.8	54

#	Article	IF	Citations
163	Pulmonary hypertension in thalassemia. Annals of the New York Academy of Sciences, 2010, 1202, 205-213.	3.8	61
164	Fertility potential in thalassemia major women: current findings and future diagnostic tools. Annals of the New York Academy of Sciences, 2010, 1202, 226-230.	3.8	17
165	Preface to Cooley's Anemia: Ninth Symposium. Annals of the New York Academy of Sciences, 2010, 1202, ix-x.	3.8	2
166	ELEVATED EXHALED CARBON MONOXIDE CONCENTRATION IN HEMOGLOBINOPATHIES AND ITS RELATION TO RED BLOOD CELL TRANSFUSION THERAPY. Pediatric Hematology and Oncology, 2010, 27, 112-121.	0.8	12
167	Neuropsychological Dysfunction and Neuroimaging Abnormalities in Neurologically Intact Adults With Sickle Cell Anemia. JAMA - Journal of the American Medical Association, 2010, 303, 1823.	7.4	241
168	Severe Sickle Cell Diseaseâ€"Pathophysiology and Therapy. Biology of Blood and Marrow Transplantation, 2010, 16, S64-S67.	2.0	41
169	HbE/Î²-Thalassemia: Basis of Marked Clinical Diversity. Hematology/Oncology Clinics of North America, 2010, 24, 1055-1070.	2.2	34
170	A Randomized Trial of the Safety and Benefit of Transfusion Vs. Standard Care In the Prevention of Sickle Cell-Related Complications In Adults: a Preliminary Report From the Phase II NHLBI Comprehensive Sickle Cell Centers (CSCC) Study of Neuropsychological Dysfunction and Neuroimaging Abnormalities In Neurologically Intact Adult Patients with Sickle Cell Disease. Blood, 2010, 116, 3221-3221.	1.4	4
171	Combined Chelation Therapy with Deferasirox and Deferoxamine In Transfusion-Dependent Thalassemia. Blood, 2010, 116, 4269-4269.	1.4	2
172	Long-Term Safety and Efficacy of Deferasirox (ExjadeÂ®) In Transfused Patients with Sickle Cell Disease Treated for up to 5 Years. Blood, 2010, 116, 845-845.	1.4	1
173	Pulmonary hypertension in hemolytic anemias. F1000 Medicine Reports, 2010, 2, .	2.9	16
174	A Phase 1B Dose-Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of FBS0701, a Novel Oral Iron Chelator for the Treatment of Chronic Iron Overload. Blood, 2010, 116, 2057-2057.	1.4	0
175	Emergency Room Utilization by California Sickle Cell Patients During Pediatric to Adult Care Transition. Blood, 2010, 116, 254-254.	1.4	1
176	The Palatability and Tolerability of Deferasirox (ExjadeÂ®) Taken with Meals, Different Liquids, or Crushed and Added to Food. Blood, 2010, 116, 5155-5155.	1.4	0
177	A New Method of Hip Coring Decompression for the Treatment of Femoral Avascular Necrosis In Sickle Cell Disease: Perioperative Safety and Preliminary Efficacy Data. Blood, 2010, 116, 264-264.	1.4	0
178	The Effect of Thalassemia and Other RBC Hemolytic Disorders and Splenectomy on the Frequency of Pulmonary Hypertension. Blood, 2010, 116, 2077-2077.	1.4	2
179	Phenomenon of Pain In Thalassemia: A Prospective Analysis by the Thalassemia Clinical Research Network (TCRN). Blood, 2010, 116, 256-256.	1.4	0
180	A Pilot Study of Epigenetic-Differentiation Therapy with Decitabine to Treat Î²-Thalassemia Intermedia. Blood, 2010, 116, 2078-2078.	1.4	21

#	Article	IF	Citations
181	Longitudinal Follow-up From Newborn Screening Reveals Deletional Hemoglobin H Disease and Hemoglobin H Constant Spring Disease Are Distinct Thalassemia Syndromes. Blood, 2010, 116, 4260-4260.	1.4	0
182	HLA type and risk of alloimmunization in sickle cell disease. American Journal of Hematology, 2009, 84, 462-464.	4.1	46
183	Hemoglobin Hâ€constant spring in North America: An alpha thalassemia with frequent complications. American Journal of Hematology, 2009, 84, 759-761.	4.1	24
184	Newborn screening for hemoglobinopathies in California. Pediatric Blood and Cancer, 2009, 52, 486-490.	1.5	145
185	Differences in the prevalence of growth, endocrine and vitamin D abnormalities among the various thalassaemia syndromes in North America. British Journal of Haematology, 2009, 146, 546-556.	2.5	153
186	Efficacy and safety of deferasirox doses of >30â€ƒmg/kg per d in patients with transfusionâ€dependent anaemia and iron overload. British Journal of Haematology, 2009, 147, 752-759.	2.5	101
187	Bone Disease in Thalassemia: A Frequent and Still Unresolved Problem. Journal of Bone and Mineral Research, 2009, 24, 543-557.	2.8	189
188	Iron Metabolism and Iron Chelation in Sickle Cell Disease. Acta Haematologica, 2009, 122, 174-183.	1.4	44
189	Alpha thalassemia majorâ€”new mutations, intrauterine management, and outcomes. Hematology American Society of Hematology Education Program, 2009, 2009, 35-41.	2.5	66
190	Serum ferritin level changes in children with sickle cell disease on chronic blood transfusion are nonlinear and are associated with iron load and liver injury. Blood, 2009, 114, 4632-4638.	1.4	98
191	Pulmonary Hypertension in Thalassemia Assessed by Echocardiography: A Report From Baseline Data of the Thalassemia Clinical Research Network Longitudinal Cohort Study.. Blood, 2009, 114, 2016-2016.	1.4	3
192	Safety of Combined Chelation Therapy with Deferasirox and Deferoxamine in Transfusion-Dependent Thalassemia.. Blood, 2009, 114, 2021-2021.	1.4	8
193	The Effect of Short-Term Simvastatin On Markers of Vascular Dysfunction in Patients with Sickle Cell Disease (SCD).. Blood, 2009, 114, 260-260.	1.4	2
194	Chelation Choices and Iron Burden Among Patients with Thalassemia in the 21st Century: a Report From the Thalassemia Clinical Research Network (TCRN) Longitudinal Cohort.. Blood, 2009, 114, 4056-4056.	1.4	5
195	Arginine Therapy for Vaso-Occlusive Pain Episodes in Sickle Cell Disease.. Blood, 2009, 114, 573-573.	1.4	5
196	Iron Overload Diminishes the Effectiveness of the Innate Immune Response in Thalassemia Major: a Possible Mechanism for Increased Infection Risk.. Blood, 2009, 114, 4071-4071.	1.4	0
197	Heightened Sulfur Amino Acid Oxidation in Plasma and Erythrocytes in Î²-Thalassemia Major.. Blood, 2009, 114, 4065-4065.	1.4	0
198	Clinical differences between children and adults with pulmonary hypertension and sickle cell disease. British Journal of Haematology, 2008, 140, 104-112.	2.5	50

#	Article	IF	Citations
199	Relative response of patients with myelodysplastic syndromes and other transfusionâ€dependent anaemias to deferasirox (ICL670): a 1â€yr prospective study. European Journal of Haematology, 2008, 80, 168-176.	2.2	210
200	Psychosocial and behavioral outcomes in children with sickle cell disease and their healthy siblings. Journal of Behavioral Medicine, 2008, 31, 506-516.	2.1	16
201	Transfusional iron burden and liver toxicity after bone marrow transplantation for acute myelogenous leukemia and hemoglobinopathies. Pediatric Blood and Cancer, 2008, 50, 319-324.	1.5	39
202	Clinical application of deferasirox: Practical patient management. American Journal of Hematology, 2008, 83, 398-402.	4.1	109
203	Hydroxycarbamideâ€induced changes in E/beta thalassemia red blood cells. American Journal of Hematology, 2008, 83, 842-845.	4.1	18
204	Erythrocyte glutamine depletion, altered redox environment, and pulmonary hypertension in sickle cell disease. Blood, 2008, 111, 402-410.	1.4	157
205	Disparity in the management of iron overload between patients with sickle cell disease and thalassemia who received transfusions. Transfusion, 2008, 48, 1971-1980.	1.6	28
206	Advances in clinical research in sickle cell disease. British Journal of Haematology, 2008, 141, 346-356.	2.5	36
207	Pulmonary Complications of Sickle Cell Disease. New England Journal of Medicine, 2008, 359, 2254-2265.	27.0	410
208	Fracture prevalence and relationship to endocrinopathy in iron overloaded patients with sickle cell disease and thalassemia. Bone, 2008, 43, 162-168.	2.9	64
209	Inflammation and oxidant-stress in Â-thalassemia patients treated with iron chelators deferasirox (ICL670) or deferoxamine: an ancillary study of the Novartis CICL670A0107 trial. Haematologica, 2008, 93, 817-825.	3.5	67
210	Patient-Reported Outcomes of Deferasirox (ExjadeÂ®, ICL670) versus Deferoxamine in Sickle Cell Disease Patients with Transfusional Hemosiderosis. Acta Haematologica, 2008, 119, 133-141.	1.4	56
211	Ethical Issues and Risk/Benefit Assessment of Iron Chelation Therapy: Advances with Deferiprone/deferoxamine Combinations and Concerns about the Safety, Efficacy and Costs of Deferasirox [Kontoghiorghes GJ, Hemoglobin 2008; 32(1â€“2):1â€“15.]. Hemoglobin, 2008, 32, 601-607.	0.8	8
212	Editorial [Hot Topic:Genetic Disorders of Hemoglobin: Sickle Cell Anemia and Thalassemia (Guest) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 2008, 8, 591-591.	1.3	0
213	DETECTION AND ASSESSMENT OF STROKE IN PATIENTS WITH SICKLE CELL DISEASE: Neuropsychological Functioning and Magnetic Resonance Imaging. Pediatric Hematology and Oncology, 2008, 25, 409-421.	0.8	42
214	Oral Iron Chelators and the Treatment of Iron Overload in Pediatric Patients With Chronic Anemia. Pediatrics, 2008, 121, 1253-1256.	2.1	17
215	Safety and efficacy of pegylated interferon Â-2a and ribavirin for the treatment of hepatitis C in patients with thalassemia. Haematologica, 2008, 93, 1247-1251.	3.5	47
216	Deferasirox (ExjadeÂ®), the Once-Daily Oral Iron Chelator, Demonstrates Safety and Efficacy in Patients with Sickle Cell Disease (SCD): 3.5-Year Follow-up.. Blood, 2008, 112, 1420-1420.	1.4	10

#	Article	IF	Citations
217	Hemoglobin H-Constant Spring in North America: A Common Alpha Thalassemia with Frequent Complications.. Blood, 2008, 112, 1880-1880.	1.4	0
218	Prolonged QTc in Sickle Cell Disease: A Potential Risk Factor for Early Death?. Blood, 2008, 112, 2476-2476.	1.4	0
219	Body Composition and Its Relationship to Growth and Bone Mass in Patients with Thalassemia. Blood, 2008, 112, 3890-3890.	1.4	0
220	Increased Nucleosomal DNA Fragmentation in Leukocytes of Thalassemia Patients.. Blood, 2008, 112, 1868-1868.	1.4	0
221	Hemoglobin E Syndromes. Hematology American Society of Hematology Education Program, 2007, 2007, 79-83.	2.5	115
222	Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with Î²-thalassemia. Clinical Therapeutics, 2007, 29, 909-917.	2.5	123
223	IRON HOMEOSTASIS DURING TRANSFUSIONAL IRON OVERLOAD IN Î²-THALASSEMIA AND SICKLE CELL DISEASE: Changes in Iron Regulatory Protein, Hepcidin, and Ferritin Expression. Pediatric Hematology and Oncology, 2007, 24, 237-243.	0.8	31
224	Morbidity and mortality in chronically transfused subjects with thalassemia and sickle cell disease: A report from the multiâ€ccenter study of iron overload. American Journal of Hematology, 2007, 82, 255-265.	4.1	149
225	Caregiving time in sickle cell disease: Psychological effects in maternal caregivers. Pediatric Blood and Cancer, 2007, 48, 64-71.	1.5	45
226	Serum ferritin underestimates liver iron concentration in transfusion independent thalassemia patients as compared to regularly transfused thalassemia and sickle cell patients. Pediatric Blood and Cancer, 2007, 49, 329-332.	1.5	121
227	A randomised comparison of deferasiroxversusdeferoxamine for the treatment of transfusional iron overload in sickle cell disease. British Journal of Haematology, 2007, 136, 501-508.	2.5	255
228	Phase Ib clinical trial of starchâ€conjugated deferoxamine (40SD02): a novel longâ€acting iron chelator. British Journal of Haematology, 2007, 138, 374-381.	2.5	39
229	Long-Term Efficacy and Safety with Deferasirox (ExjadeÂ®, ICL670), a Once-Daily Oral Iron Chelator, in Pediatric Patients.. Blood, 2007, 110, 2774-2774.	1.4	9
230	Long-Term Treatment with Deferasirox (ExjadeÂ®, ICL670), a Once-Daily Oral Iron Chelator, Is Effective in Patients with Transfusion-Dependent Anemias.. Blood, 2007, 110, 2777-2777.	1.4	10
231	Long-Term Efficacy and Safety of Deferasirox (ExjadeÂ®, ICL670), a Once-Daily Oral Iron Chelator, in Patients with Sickle Cell Disease (SCD).. Blood, 2007, 110, 3395-3395.	1.4	5
232	Candidate Gene Polymorphisms and Their Association with TCD Velocities in Children with Sickle Cell Disease.. Blood, 2007, 110, 429-429.	1.4	8
233	Pulmonary Hypertension in Thalassemia: Association with Hemolysis, Arginine Metabolism Dysregulation, and a Hypercoagulable State. Advances in Pulmonary Hypertension, 2007, 6, 31-38.	0.1	10
234	Neuropsychological (NP) Dysfunction and Neuroimaging Abnormalities in Neurologically Intact Adult Patients with Sickle Cell Disease (SCD).. Blood, 2007, 110, 428-428.	1.4	0

#	Article	IF	Citations
235	High Frequency of Asthma, Sepsis and Acute Chest Syndrome in Children with Sickle Cell Disease and Pulmonary Hypertension.. Blood, 2007, 110, 3782-3782.	1.4	0
236	Leukocyte Apoptosis and Mitochondrial Dysfunction in Î²-Thalassemia Patients Treated with Deferasirox or Deferoxamine.. Blood, 2007, 110, 2773-2773.	1.4	0
237	Bone mineral density in children with sickle cell anemia. Pediatric Blood and Cancer, 2006, 47, 901-906.	1.5	74
238	Oxidative stress and inflammation in ironâ€overloaded patients with Î²â€thalassaemia or sickle cell disease. British Journal of Haematology, 2006, 135, 254-263.	2.5	260
239	Increased prevalence of ironâ€overload associated endocrinopathy in thalassaemia versus sickleâ€cell disease. British Journal of Haematology, 2006, 135, 574-582.	2.5	178
240	Dose-Escalation Study of ICA-17043 in Patients with Sickle Cell Disease. Pharmacotherapy, 2006, 26, 1557-1564.	2.6	51
241	Pulmonary hypertension in thalassemia: Association with platelet activation and hypercoagulable state. American Journal of Hematology, 2006, 81, 670-675.	4.1	135
242	Physical Therapy Alone Compared with Core Decompression and Physical Therapy for Femoral Head Osteonecrosis in Sickle Cell Disease. Journal of Bone and Joint Surgery - Series A, 2006, 88, 2573-2582.	3.0	88
243	PREVALENCE OF HFE MUTATIONS IN CALIFORNIA NEWBORNS. Pediatric Hematology and Oncology, 2006, 23, 507-516.	0.8	8
244	Collaborative Data Project [C-DATA] of the Comprehensive Sickle Cell Centers Program.. Blood, 2006, 108, 1200-1200.	1.4	5
245	Oral Arginine Increases Erythrocyte Glutathione Levels in Sickle Cell Disease: Implications for Pulmonary Hypertension.. Blood, 2006, 108, 1208-1208.	1.4	7
246	Leukocyte Apoptosis and Inflammation in Iron-Overloaded Patients with Sickle Cell Disease or Î²-Thalassemia: A Mechanism for Increased Stroke and Disease Severity in Sickle Cell Disease.. Blood, 2006, 108, 1233-1233.	1.4	1
247	MRI Assessment of Pituitary Iron and Volume in Thalassemia, and Relation to Hypothalamic-Pituitary-Gonadal Axis Function (HPG): A Feasibility Study.. Blood, 2006, 108, 1778-1778.	1.4	2
248	Safety and Efficacy of Peginterferon Alfa-2a and Ribavirin for Hepatitis C in Thalassemia.. Blood, 2006, 108, 558-558.	1.4	4
249	PHYSICAL THERAPY ALONE COMPARED WITH CORE DECOMPRESSION AND PHYSICAL THERAPY FOR FEMORAL HEAD OSTEONECROSIS IN SICKLE CELL DISEASE. Journal of Bone and Joint Surgery - Series A, 2006, 88, 2573-2582.	3.0	41
250	Do Transfusions of Packed Red Blood Cells Decrease Renal Function in Adult Sickle Cell Patients?.. Blood, 2006, 108, 3793-3793.	1.4	0
251	Liver Iron Measurement by SQUID Compared to Liver Biopsy.. Blood, 2006, 108, 3826-3826.	1.4	2
252	Left Ventricular Dysfunction in Chronically Transused Patients with Sickle Cell Anemia and Thalassemia.. Blood, 2006, 108, 3745-3745.	1.4	0

#	Article	IF	Citations
253	Iron Overload in Acute Myelogenous Leukemia after Bone Marrow Transplantation.. Blood, 2006, 108, 5336-5336.	1.4	0
254	Erythrocyte Glutathione Depletion Is Associated with Severity of Anemia and Pulmonary Hypertension in Patients with Sickle Cell Disease.. Blood, 2006, 108, 788-788.	1.4	1
255	Bone Mineral Density in Transfusion Independent Thalassemia Patients.. Blood, 2006, 108, 3353-3353.	1.4	0
256	Using qualitative and quantitative strategies to evaluate knowledge and perceptions about sickle cell disease and sickle cell trait. Journal of the National Medical Association, 2006, 98, 704-10.	0.8	55
257	Changing Patterns of Thalassemia Worldwide. Annals of the New York Academy of Sciences, 2005, 1054, 18-24.	3.8	178
258	Hemoglobin E-Î²-Thalassemia: Progress Report from the International Study Group. Annals of the New York Academy of Sciences, 2005, 1054, 33-39.	3.8	20
259	Single and Combination Drug Therapy for Fetal Hemoglobin Augmentation in Hemoglobin E-Î²0-Thalassemia: Considerations for Treatment. Annals of the New York Academy of Sciences, 2005, 1054, 250-256.	3.8	14
260	Treatment of Hepatitis C Virus Infection in Thalassemia. Annals of the New York Academy of Sciences, 2005, 1054, 290-299.	3.8	20
261	Measuring Chromosome Breaks in Patients with Thalassemia. Annals of the New York Academy of Sciences, 2005, 1054, 439-444.	3.8	14
262	Hemolysis-Associated Pulmonary Hypertension in Thalassemia. Annals of the New York Academy of Sciences, 2005, 1054, 481-485.	3.8	96
263	Quality of Life in Patients with Thalassemia Intermedia Compared to Thalassemia Major. Annals of the New York Academy of Sciences, 2005, 1054, 457-461.	3.8	80
264	Outcomes of Preimplantation Genetic Diagnosis Therapy in Treatment of Î²-Thalassemia: A Retrospective Analysis. Annals of the New York Academy of Sciences, 2005, 1054, 500-503.	3.8	21
265	Utility of Holter Electrocardiogram in Iron-Overloaded Hemoglobinopathies. Annals of the New York Academy of Sciences, 2005, 1054, 476-480.	3.8	17
266	A Simple Model to Assess and Improve Adherence to Iron Chelation Therapy with Deferoxamine in Patients with Thalassemia. Annals of the New York Academy of Sciences, 2005, 1054, 486-491.	3.8	14
267	Fetal haemoglobin augmentation in E/beta0 thalassaemia: clinical and haematological outcome. British Journal of Haematology, 2005, 131, 378-388.	2.5	59
268	Comparison of organ dysfunction in transfused patients with SCD or Î² thalassemia. American Journal of Hematology, 2005, 80, 70-74.	4.1	125
269	Can peak systolic velocities be used for prediction of stroke in sickle cell anemia?. Pediatric Radiology, 2005, 35, 66-72.	2.0	37
270	Barriers to adherence of deferoxamine usage in sickle cell disease. Pediatric Blood and Cancer, 2005, 44, 500-507.	1.5	48

#	Article	IF	Citations
271	Variability in Hepatic Iron Concentration in Percutaneous Needle Biopsy Specimens From Patients With Transfusional Hemosiderosis. American Journal of Clinical Pathology, 2005, 123, 146-152.	0.7	52
272	Dysregulated Arginine Metabolism, Hemolysis-Associated Pulmonary Hypertension, and Mortality in Sickle Cell Disease. JAMA - Journal of the American Medical Association, 2005, 294, 81.	7.4	619
273	Bone and Joint Disease in Sickle Cell Disease. Hematology/Oncology Clinics of North America, 2005, 19, 929-941.	2.2	56
274	Changes in the Epidemiology of Thalassemia in North America: A New Minority Disease. Pediatrics, 2005, 116, e818-e825.	2.1	110
275	Clinical Evaluation of Avascular Necrosis in Patients With Sickle Cell Disease: Childrenâ€™s Hospital Oakland Hip Evaluation Scaleâ€"A Modification of the Harris Hip Score. Archives of Physical Medicine and Rehabilitation, 2005, 86, 1369-1375.	0.9	41
276	Abnormal Pulmonary Function in Adults and Children with Sickle Cell Disease.. Blood, 2005, 106, 2319-2319.	1.4	1
277	Control of Oxidant-Stress and Inflammation by Iron Chelators Deferasirox (ICL670) or Deferoxamine in Î²-Thalassemia: An Ancillary Study of the Novartis CICL670A0107 Trial.. Blood, 2005, 106, 3598-3598.	1.4	2
278	Increased Chromosomal Breaks in Sickle Cell Disease as Evidenced by the Presence of Micronuclei in Erythrocytes.. Blood, 2005, 106, 3807-3807.	1.4	0
279	Hospitalization Rate and Regional Differences in Comprehensive Care in Transfused Patients with Sickle Cell Disease Compared to Thalassemia: A Report from the Multi-Center Study of Iron Overload.. Blood, 2005, 106, 3189-3189.	1.4	0
280	Dysregulated Arginine Metabolism and Elevated Arginase Activity in Thalassemia.. Blood, 2005, 106, 3644-3644.	1.4	0
281	High Prevalence of Fractures and Bone Pain in Thalassemia: The Thalassemia Clinical Research Network Experience.. Blood, 2005, 106, 2706-2706.	1.4	0
282	Serum Ferritin and Liver Iron Concentration in Patients with Iron Overload.. Blood, 2005, 106, 3833-3833.	1.4	0
283	Quality of Life (QOL) in Sickle Cell Disease (SCD).. Blood, 2005, 106, 1324-1324.	1.4	0
284	Thalassemia. Hematology American Society of Hematology Education Program, 2004, 2004, 14-34.	2.5	181
285	Pulmonary Hypertension in Sickle Cell Disease. New England Journal of Medicine, 2004, 350, 857-859.	27.0	92
286	Hematologic problems in immigrants from Southeast Asia. Hematology/Oncology Clinics of North America, 2004, 18, 1405-1422.	2.2	13
287	The role of fetal hemoglobinâ€"enhancing agents in thalassemia. Seminars in Hematology, 2004, 41, 17-22.	3.4	23
288	Stroke and conversion to high risk in children screened with transcranial Doppler ultrasound during the STOP study. Blood, 2004, 103, 3689-3694.	1.4	156

#	Article	IF	Citations
289	Gene interactions and stroke risk in children with sickle cell anemia. Blood, 2004, 103, 2391-2396.	1.4	178
290	Pulmonary Hypertension in Sickle Cell Disease: A Common Complication for Both Adults and Children.. Blood, 2004, 104, 1666-1666.	1.4	1
291	Progression of Organ Dysfunction in Iron Overloaded Patients with Î² Thalassemia and Sickle Cell Disease.. Blood, 2004, 104, 1683-1683.	1.4	1
292	Progression of Avascular Necrosis of the Hip in Sickle Cell Disease: 2 Year Follow-Up of Randomized Trial of Aggressive Physical Therapy and Hip Coring Decompression.. Blood, 2004, 104, 1685-1685.	1.4	1
293	The Arginine-to-Ornithine Ratio: Biomarker of Arginase Activity and Predictor of Mortality in Sickle Cell Disease.. Blood, 2004, 104, 237-237.	1.4	6
294	An Effective Program to Resolve Ambiguous Results from State Newborn Hemoglobinopathy Screening.. Blood, 2004, 104, 3563-3563.	1.4	1
295	Biotin-Labeled RBC Survival in Thalassemia and Impact of Treatment.. Blood, 2004, 104, 3616-3616.	1.4	2
296	Barriers to Deferoxamine Adherence for Adults with Sickle Cell Disease.. Blood, 2004, 104, 3760-3760.	1.4	2
297	Assessing Compliance to Iron Chelation Therapy in Patients with Thalassemia.. Blood, 2004, 104, 3787-3787.	1.4	2
298	Serum Ferritin a Predictor of Iron Overload in Patients with Thalassemia and Sickle Cell Disease?.. Blood, 2004, 104, 3789-3789.	1.4	4
299	Low Bone Mass in Thalassemia: The Thalassemia Clinical Research Network (TCRN) Experience.. Blood, 2004, 104, 3613-3613.	1.4	0
300	Pulmonary Hypertension: A Common Complication in Thalassemia.. Blood, 2004, 104, 3612-3612.	1.4	0
301	Toxic Unbound Iron and Membrane Injury in b-Thalassemia and Sickle Cell Disease: Elevated Non-Transferrin Bound Iron (NTBI) and Malondialdehyde (MDA).. Blood, 2004, 104, 3608-3608.	1.4	0
302	Quality of Life in Patients with Thalassemia.. Blood, 2004, 104, 3786-3786.	1.4	1
303	Utility of Holter Electrocardiogram Monitoring in Iron over Loaded Î² Thalassemia and Sickle Cell Disease.. Blood, 2004, 104, 3784-3784.	1.4	0
304	The Outcomes of Preimplantation Genetic Diagnosis Therapy in Treatment of Î² Thalassemia - a Retrospective Analysis.. Blood, 2004, 104, 3783-3783.	1.4	0
305	Pulmonary Hypertension in Thalassemia: Association with Platelet Activation and Hypercoagulable State.. Blood, 2004, 104, 3618-3618.	1.4	0
306	Early Hepatitis C Viral Response (EVR) to Peginterferon Alfa 2a and Ribavirin in Patients with Î² Thalassemia.. Blood, 2004, 104, 3624-3624.	1.4	0

#	Article	IF	Citations
307	Invasive pneumococcal infections in children with sickle cell disease in the era of penicillin prophylaxis, antibiotic resistance, and 23-valent pneumococcal polysaccharide vaccination. Journal of Pediatrics, 2003, 143, 438-444.	1.8	133
308	Liver Ferritin Subunit Ratios in Neonatal Hemochromatosis. Pediatric Hematology and Oncology, 2003, 20, 229-235.	0.8	9
309	Effect of Hydroxyurea on Mortality and Morbidity in Adult Sickle Cell Anemia. JAMA - Journal of the American Medical Association, 2003, 289, 1645.	7.4	741
310	Managing sickle cell disease. BMJ: British Medical Journal, 2003, 327, 1151-1155.	2.3	139
311	Arginine Therapy. American Journal of Respiratory and Critical Care Medicine, 2003, 168, 63-69.	5.6	302
312	Chlamydia pneumoniae and Acute Chest Syndrome in Patients With Sickle Cell Disease. Journal of Pediatric Hematology/Oncology, 2003, 25, 46-55.	0.6	52
313	Hydroxyurea and Arginine Therapy: Impact on Nitric Oxide Production in Sickle Cell Disease. Journal of Pediatric Hematology/Oncology, 2003, 25, 629-634.	0.6	79
314	Distinct HLA associations by stroke subtype in children with sickle cell anemia. Blood, 2003, 101, 2865-2869.	1.4	75
315	Deferiprone and hepatic fibrosis. Blood, 2003, 101, 5089-5091.	1.4	18
316	Mycoplasma Disease and Acute Chest Syndrome in Sickle Cell Disease. Pediatrics, 2003, 112, 87-95.	2.1	70
317	Using quality improvement strategies to enhance pediatric pain assessment. International Journal for Quality in Health Care, 2002, 14, 39-47.	1.8	95
318	Pancytopenia Induced by Hypothermia. Journal of Pediatric Hematology/Oncology, 2002, 24, 681-684.	0.6	18
319	Longitudinal Changes in Ferritin During Chronic Transfusion: A Report From the Stroke Prevention Trial in Sickle Cell Anemia (STOP). Journal of Pediatric Hematology/Oncology, 2002, 24, 284-290.	0.6	45
320	Novel Therapeutic Approaches in Sickle Cell Disease. Hematology American Society of Hematology Education Program, 2002, 2002, 10-34.	2.5	9
321	Longitudinal changes in brain magnetic resonance imaging findings in children with sickle cell disease. Blood, 2002, 99, 3014-3018.	1.4	319
322	New therapies in sickle cell disease. Lancet, The, 2002, 360, 629-631.	13.7	70
323	Effect of hydroxyurea on growth in children with sickle cell anemia: Results of the HUG-KIDS study. Journal of Pediatrics, 2002, 140, 225-229.	1.8	89
324	Diseases of iron metabolism. Pediatric Clinics of North America, 2002, 49, 893-909.	1.8	13

#	Article	IF	Citations
325	Assessment of Sickle Cell Pain in Children and Young Adults Using the Adolescent Pediatric Pain Tool. Journal of Pain and Symptom Management, 2002, 23, 114-120.	1.2	55
326	Central venous catheter complications in sickle cell disease. American Journal of Hematology, 2002, 69, 103-108.	4.1	64
327	Universal Newborn Screening for Hb H Disease in California. Genetic Testing and Molecular Biomarkers, 2001, 5, 93-100.	1.7	87
328	Neuropsychologic performance in school-aged children with sickle cell disease: A report from the Cooperative Study of Sickle Cell Disease. Journal of Pediatrics, 2001, 139, 391-397.	1.8	248
329	Silent infarction as a risk factor for overt stroke in children with sickle cell anemia: A report from the Cooperative Study of Sickle Cell Disease. Journal of Pediatrics, 2001, 139, 385-390.	1.8	256
330	Consensus document for transfusion-related iron overload. Seminars in Hematology, 2001, 38, 2-4.	3.4	36
331	Current issues with blood transfusions in sickle cell disease. Seminars in Hematology, 2001, 38, 14-22.	3.4	115
332	Correlation of abnormal intracranial vessel velocity, measured by transcranial Doppler ultrasonography, with abnormal conjunctival vessel velocity, measured by computer-assisted intravital microscopy, in sickle cell disease. Blood, 2001, 97, 3401-3404.	1.4	34
333	A novel multilocus genotyping assay to identify genetic predictors of stroke in sickle cell anaemia. British Journal of Haematology, 2001, 114, 718-720.	2.5	28
334	Prospective RBC phenotype matching in a stroke-prevention trial in sickle cell anemia: a multicenter transfusion trial. Transfusion, 2001, 41, 1086-1092.	1.6	296
335	Stem Cell Transplantation for Sickle Cell Disease: Can We Reduce the Toxicity?. Fetal and Pediatric Pathology, 2001, 20, 73-86.	0.3	5
336	Current issues with blood transfusions in sickle cell disease. Seminars in Hematology, 2001, 38, 14-22.	3.4	95
337	Transfusion Therapy: A Coming-of-Age Treatment for Patients With Sickle Cell Disease. The American Journal of Pediatric Hematology/oncology, 2001, 23, 197-202.	1.3	13
338	Acute Chest Syndrome in Sickle Cell Disease: Pathophysiology and Management. Journal of Intensive Care Medicine, 2000, 15, 159-166.	2.8	4
339	Outreach Strategies for Southeast Asian Communities: Experience, Practice, and Suggestions for Approaching Southeast Asian Immigrant and Refugee Communities to Provide Thalassemia Education and Trait Testing. The American Journal of Pediatric Hematology/oncology, 2000, 22, 588-592.	1.3	17
340	Changing Outcome of Homozygous Î±-Thalassemia: Cautious Optimism. The American Journal of Pediatric Hematology/oncology, 2000, 22, 539-542.	1.3	57
341	Patterns of Arginine and Nitric Oxide in Patients With Sickle Cell Disease With Vaso-occlusive Crisis and Acute Chest Syndrome. The American Journal of Pediatric Hematology/oncology, 2000, 22, 515-520.	1.3	176
342	Report of Proceedings: 1999 International Conference on E-Î² Thalassemia. The American Journal of Pediatric Hematology/oncology, 2000, 22, 550.	1.3	6

#	Article	IF	Citations
343	Arginine therapy: a novel strategy to induce nitric oxide production in sickle cell disease. British Journal of Haematology, 2000, 111, 498-500.	2.5	38
344	Acute Chest Syndrome in Sickle Cell Disease: Pathophysiology and Management. Journal of Intensive Care Medicine, 2000, 15, 159-166.	2.8	6
345	Evidence for HLA-related susceptibility for stroke in children with sickle cell disease. Blood, 2000, 95, 3562-3567.	1.4	59
346	Severity of iron overload in patients with sickle cell disease receiving chronic red blood cell transfusion therapy. Blood, 2000, 96, 76-79.	1.4	177
347	Alloimmunization and erythrocyte autoimmunization in transfusion-dependent thalassemia patients of predominantly Asian descent. Blood, 2000, 96, 3369-3373.	1.4	263
348	Secretory phospholipase A2 predicts impending acute chest syndrome in sickle cell disease. Blood, 2000, 96, 3276-3278.	1.4	92
349	Causes and Outcomes of the Acute Chest Syndrome in Sickle Cell Disease. New England Journal of Medicine, 2000, 342, 1855-1865.	27.0	1,062
350	Sickle-cell disease not identified by newborn screening because of prior transfusion. Journal of Pediatrics, 2000, 136, 248-250.	1.8	29
351	Arginine therapy: a novel strategy to induce nitric oxide production in sickle cell disease. SHORT REPORT. British Journal of Haematology, 2000, 111, 498-500.	2.5	102
352	Use of Hydroxyurea in Children Ages 2 to 5 Years With Sickle Cell Disease. The American Journal of Pediatric Hematology/oncology, 2000, 22, 330-334.	1.3	44
353	Multicenter Comparison of Magnetic Resonance Imaging and Transcranial Doppler Ultrasonography in the Evaluation of the Central Nervous System in Children With Sickle Cell Disease. The American Journal of Pediatric Hematology/oncology, 2000, 22, 335-339.	1.3	83
354	Severity of iron overload in patients with sickle cell disease receiving chronic red blood cell transfusion therapy. Blood, 2000, 96, 76-79.	1.4	8
355	Alloimmunization and erythrocyte autoimmunization in transfusion-dependent thalassemia patients of predominantly Asian descent. Blood, 2000, 96, 3369-3373.	1.4	20
356	Evidence for HLA-related susceptibility for stroke in children with sickle cell disease. Blood, 2000, 95, 3562-3567.	1.4	0
357	Secretory phospholipase A2 predicts impending acute chest syndrome in sickle cell disease. Blood, 2000, 96, 3276-3278.	1.4	26
358	Clinician Assessment for Acute Chest Syndrome in Febrile Patients With Sickle Cell Disease: Is It Accurate Enough?. Annals of Emergency Medicine, 1999, 34, 64-69.	0.6	53
359	Erythrocytapheresis for chronically transfused children with sickle cell disease: An effective method for maintaining a low hemoglobin S level and reducing iron overload. Journal of Clinical Apheresis, 1999, 14, 122-125.	1.3	73
360	Deferoxamine treatment during pregnancy: Is it harmful?. American Journal of Hematology, 1999, 60, 24-26.	4.1	57

#	Article	IF	Citations
361	The perioperative complication rate of orthopedic surgery in sickle cell disease: Report of the national sickle cell surgery study group. , 1999, 62, 129-138.		128
362	Hydroxyurea and sodium phenylbutyrate therapy in thalassemia intermedia. , 1999, 62, 221-227.		48
363	Bone disease in Î²-thalassaemia. Lancet, The, 1999, 354, 881-882.	13.7	13
364	Tonsillectomy, Adenoidectomy, and Myringotomy in Sickle Cell Disease. Journal of Pediatric Hematology/Oncology, 1999, 21, 129-135.	0.6	49
365	The perioperative complication rate of orthopedic surgery in sickle cell disease: Report of the national sickle cell surgery study group. American Journal of Hematology, 1999, 62, 129-138.	4.1	3
366	Erythrocytapheresis for chronically transfused children with sickle cell disease: An effective method for maintaining a low hemoglobin S level and reducing iron overload. Journal of Clinical Apheresis, 1999, 14, 122-125.	1.3	3
367	Effects of Red Blood Cell Transfusion on Resting Energy Expenditure in Adolescents with Sickle Cell Anemia. Journal of Pediatric Gastroenterology and Nutrition, 1999, 29, 127-131.	1.8	12
368	Transfusion practice for patients with sickle cell disease. Current Opinion in Hematology, 1999, 6, 432.	2.5	12
369	Related Cord Blood Banking for Patients with Hemoglobinopathies. Pediatric Research, 1999, 45, 149A-149A.	2.3	0
370	Association of HLA Type with Risk of Cerebral Infarction in Children with Sickle Cell Disease. Pediatric Research, 1999, 45, 147A-147A.	2.3	0
371	Low Molecular Weight Heparin in Sickle Cell Disease. Pediatric Research, 1999, 45, 153A-153A.	2.3	0
372	Preliminary Report: Hydroxyurea Produces Significant Clinical Response in Thalassemia Intermedia. Annals of the New York Academy of Sciences, 1998, 850, 461-462.	3.8	10
373	The Social Impact of Migration on Disease: Cooley's Anemia, Thalassemia, and New Asian Immigrants. Annals of the New York Academy of Sciences, 1998, 850, 509-511.	3.8	12
374	Stroke Prevention Trial in Sickle Cell Anemia. Contemporary Clinical Trials, 1998, 19, 110-129.	1.9	228
375	Surgery in patients with hemoglobin SC disease. , 1998, 57, 101-108.		65
376	Correction of the anemia of epidermolysis bullosa with intravenous iron and erythropoietin. Journal of Pediatrics, 1998, 132, 871-873.	1.8	32
377	Prevention of a First Stroke by Transfusions in Children with Sickle Cell Anemia and Abnormal Results on Transcranial Doppler Ultrasonography. New England Journal of Medicine, 1998, 339, 5-11.	27.0	1,699
378	The natural history of sickle cell disease. Current Opinion in Pediatrics, 1998, 10, 49-52.	2.0	26

#	Article	IF	Citations
379	Hydroxyurea in Children with Sickle Cell Disease. Journal of Pediatric Hematology/Oncology, 1998, 20, 26-31.	0.6	67
380	Acute chest syndrome and sickle cell disease. Current Opinion in Hematology, 1998, 5, 89-92.	2.5	27
381	New therapies and approaches to transfusion in sickle cell disease in children. Current Opinion in Pediatrics, 1997, 9, 41-45.	2.0	8
382	Natural History of Blood Pressure in Sickle Cell Disease: Risks for Stroke and Death Associated with Relative Hypertension in Sickle Cell Anemia. American Journal of Medicine, 1997, 102, 171-177.	1.5	224
383	Umbilical cord blood stem cells: Application for the treatment of patients with hemoglobinopathies. Journal of Pediatrics, 1997, 130, 695-703.	1.8	35
384	Acute Chest Syndrome in Sickle Cell Disease: Clinical Presentation and Course. Blood, 1997, 89, 1787-1792.	1.4	508
385	Decrease of Very Late Activation Antigen-4 and CD36 on Reticulocytes in Sickle Cell Patients Treated With Hydroxyurea. Blood, 1997, 89, 2554-2559.	1.4	139
386	Influence of Penicillin Prophylaxis on Antimicrobial Resistance in Nasopharyngeal S. Pneumoniae among Children with Sickle Cell Anemia. The American Journal of Pediatric Hematology/oncology, 1997, 19, 327-333.	1.3	28
387	Acute Chest Syndrome in Sickle Cell Disease: Clinical Presentation and Course. Blood, 1997, 89, 1787-1792.	1.4	21
388	PULMONARY COMPLICATIONS. Hematology/Oncology Clinics of North America, 1996, 10, 1275-1287.	2.2	22
389	Serotype-specific immunoglobulin G antibody responses to pneumococcal polysaccharide vaccine in children with sickle cell anemia: Effects of continued penicillin prophylaxis. Journal of Pediatrics, 1996, 129, 828-835.	1.8	45
390	Ototoxicity in Hemoglobinopathy Patients Chelated with Desferrioxamine. Journal of Pediatric Hematology/Oncology, 1996, 18, 42-45.	0.6	18
391	Newborn Screening for Sickle Cell Disease. Journal of Pediatric Hematology/Oncology, 1996, 18, 36-41.	0.6	77
392	Core decompression in avascular necrosis of the hip in sickle-cell disease. , 1996, 52, 103-107.		67
393	Core decompression in avascular necrosis of the hip in sickleâ€cell disease. American Journal of Hematology, 1996, 52, 103-107.	4.1	4
394	LIVER TRANSPLANTATION IN A CHILD WITH SICKLE CELL ANEMIA. Transplantation, 1995, 59, 1490-1492.	1.0	29
395	Discontinuing penicillin prophylaxis in children with sickle cell anemia. Journal of Pediatrics, 1995, 127, 685-690.	1.8	195
396	Risk of recurrent stroke in patients with sickle cell disease treated with erythrocyte transfusions. Journal of Pediatrics, 1995, 126, 896-899.	1.8	346

#	Article	IF	Citations
397	Effects of a long-term transfusion regimen on sickle cell-related illnesses. Journal of Pediatrics, 1994, 125, 909-911.	1.8	85
398	Universal Screening for Hemoglobinopathies Using High-Performance Liquid Chromatography: Clinical Results of 2.2 Million Screens. European Journal of Human Genetics, 1994, 2, 262-271.	2.8	50
399	A Short-Term Trial of Butyrate to Stimulate Fetal-Globin-Gene Expression in the Î²-Globin Disorders. New England Journal of Medicine, 1993, 328, 81-86.	27.0	443
400	Pain in Sickle Cell Disease. New England Journal of Medicine, 1991, 325, 11-16.	27.0	1,431
401	Sickle Cell Disease in a Patient with Sickle Cell Trait and Compound Heterozygosity for Hemoglobin S and Hemoglobin Quebecâ€“Chori. New England Journal of Medicine, 1991, 325, 1150-1154.	27.0	58
402	Alloimmunization in Sickle Cell Anemia and Transfusion of Racially Unmatched Blood. New England Journal of Medicine, 1990, 322, 1617-1621.	27.0	542
403	Vitamin C Deficiency in Patients with Sickle Cell Anemia. Journal of Pediatric Hematology/Oncology, 1990, 12, 262.	0.6	26
404	The Role of Oxidation in Diseases of the Human Erythrocyte. , 1990, , 34-47.		0
405	Letter to the editor. Journal of Adolescent Health Care: Official Publication of the Society for Adolescent Medicine, 1988, 9, 87.	0.3	0
406	Suggested Guidelines for the Treatment of Children with Sickle Cell Anemia. Hematology/Oncology Clinics of North America, 1987, 1, 483-501.	2.2	30
407	Prophylaxis with Oral Penicillin in Children with Sickle Cell Anemia. New England Journal of Medicine, 1986, 314, 1593-1599.	27.0	1,048
408	GROWTH RETARDATION IN SICKLE-CELL DISEASE TREATED BY NUTRITIONAL SUPPORT. Lancet, The, 1985, 325, 903-906.	13.7	69
409	Inadequate erythroid response to hypoxia in cystic fibrosis. Journal of Pediatrics, 1984, 105, 15-21.	1.8	25
410	Concurrent Sickle-Cell Anemia and Î±-Thalassemia. New England Journal of Medicine, 1982, 306, 270-274.	27.0	252
411	PEROXIDATION, VITAMIN E, AND SICKLE-CELL ANEMIA. Annals of the New York Academy of Sciences, 1982, 393, 323-335.	3.8	56
412	Sickle Cell Anemia and Related Hemoglobinopathies. Pediatric Clinics of North America, 1980, 27, 429-447.	1.8	56
413	Unstable Hemoglobins, Hemoglobins with Altered Oxygen Affinity, and M-Hemoglobins. Pediatric Clinics of North America, 1980, 27, 421-428.	1.8	3
414	Current treatment of sickle cell disease. Current Problems in Pediatrics, 1980, 10, 1-64.	1.1	7

#	Article	IF	Citations
415	Anemia associated with rheumatoid arthritis. Journal of Pediatrics, 1979, 94, 678.	1.8	4
416	Anemia in the Newborn Period. Pediatric Annals, 1979, 8, 10-37.	0.8	4